Skip to main content

Table 3 Qualitative variables of the subjects as a function of the diagnosis of premorbid metabolic syndrome based on the WHO proposal

From: Screening premorbid metabolic syndrome in community pharmacies: a cross-sectional descriptive study

   Total n = 621 Pre-MetS n = 136 Non Pre-MetS n = 485 p
Sex 48.0 (44.1-51.9) 55.9 (47.6-64.2) 45.8 (41.4-50.2)  
  52.0 (48.1-55.9) 44.1 (35.8-52.4) 54.2 (49.8-58.6) <0.001
AC drugs   30.0 (26.4-33.6) 49.3 (40.9-57.7) 24.5 (20.7-28.3) <0.001
AH drugs   32.7 (29.0-36.4) 49.3 (40.9-57.7) 28.0 (24.0-32.0) <0.001
Smoking habit   30.1 (26.5-33.7) 27.9 (20.4-35.4) 30.7 (26.6-34.8) 0.597
Physical inactivity   58.9 (55.0-62.8) 69.9 (62.2-77.6) 55.9 (51.5-60.3) 0.004
BMI <25 42.4 (38.5-46.3) 12.5 (7.0-18.1) 50.7 (46.6-55.2)  
  ≥25 57.6 (53.7-61.5) 87.5 (81.9-93.1) 49.3 (44.9-53.7) <0.001
  1. p ≤ 0.05 is considered to be statistically significant.
  2. Data are expressed as percentages (95% Confidence Interval).
  3. Pre-MetS premorbid metabolic syndrome; AC drugs: pharmacological treatment of hypercholesterolemia or hypertriglyceridemia; AH Drugs: pharmacological treatment of hypertension.